vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Sensata Technologies Holding plc (ST). Click either name above to swap in a different company.

Sensata Technologies Holding plc is the larger business by last-quarter revenue ($934.8M vs $487.7M, roughly 1.9× CLOVER HEALTH INVESTMENTS, CORP.). Sensata Technologies Holding plc runs the higher net margin — 9.3% vs -10.1%, a 19.4% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 2.6%). Sensata Technologies Holding plc produced more free cash flow last quarter ($104.6M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -5.0%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Sensata Technologies Holding plc is a global industrial technology company that designs, manufactures and sells a broad portfolio of sensing, electrical protection and control solutions. Its products serve automotive, industrial, aerospace, HVAC, telecommunications and heavy vehicle end markets, catering to manufacturing and enterprise clients across the world.

CLOV vs ST — Head-to-Head

Bigger by revenue
ST
ST
1.9× larger
ST
$934.8M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+42.2% gap
CLOV
44.7%
2.6%
ST
Higher net margin
ST
ST
19.4% more per $
ST
9.3%
-10.1%
CLOV
More free cash flow
ST
ST
$173.6M more FCF
ST
$104.6M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-5.0%
ST

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
ST
ST
Revenue
$487.7M
$934.8M
Net Profit
$-49.3M
$87.1M
Gross Margin
30.6%
Operating Margin
-10.1%
15.1%
Net Margin
-10.1%
9.3%
Revenue YoY
44.7%
2.6%
Net Profit YoY
-123.2%
24.6%
EPS (diluted)
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
ST
ST
Q1 26
$934.8M
Q4 25
$487.7M
$917.9M
Q3 25
$496.6M
$932.0M
Q2 25
$477.6M
$943.4M
Q1 25
$462.3M
$911.3M
Q4 24
$337.0M
$907.7M
Q3 24
$331.0M
$982.8M
Q2 24
$356.3M
$1.0B
Net Profit
CLOV
CLOV
ST
ST
Q1 26
$87.1M
Q4 25
$-49.3M
$63.2M
Q3 25
$-24.4M
$-162.5M
Q2 25
$-10.6M
$60.7M
Q1 25
$-1.3M
$69.9M
Q4 24
$-22.1M
$5.8M
Q3 24
$-9.2M
$-25.0M
Q2 24
$7.4M
$71.7M
Gross Margin
CLOV
CLOV
ST
ST
Q1 26
30.6%
Q4 25
29.0%
Q3 25
27.8%
Q2 25
30.3%
Q1 25
29.9%
Q4 24
27.1%
Q3 24
24.5%
28.6%
Q2 24
30.3%
30.0%
Operating Margin
CLOV
CLOV
ST
ST
Q1 26
15.1%
Q4 25
-10.1%
10.9%
Q3 25
-4.9%
-13.2%
Q2 25
-2.2%
14.6%
Q1 25
-0.3%
13.4%
Q4 24
-6.4%
8.1%
Q3 24
-2.7%
-20.3%
Q2 24
2.0%
12.5%
Net Margin
CLOV
CLOV
ST
ST
Q1 26
9.3%
Q4 25
-10.1%
6.9%
Q3 25
-4.9%
-17.4%
Q2 25
-2.2%
6.4%
Q1 25
-0.3%
7.7%
Q4 24
-6.6%
0.6%
Q3 24
-2.8%
-2.5%
Q2 24
2.1%
6.9%
EPS (diluted)
CLOV
CLOV
ST
ST
Q1 26
$0.59
Q4 25
$0.45
Q3 25
$-1.12
Q2 25
$0.41
Q1 25
$0.47
Q4 24
$0.05
Q3 24
$-0.17
Q2 24
$0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
ST
ST
Cash + ST InvestmentsLiquidity on hand
$78.3M
$635.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$2.9B
Total Assets
$541.0M
$6.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
ST
ST
Q1 26
$635.1M
Q4 25
$78.3M
$573.0M
Q3 25
$791.3M
Q2 25
$661.8M
Q1 25
$588.1M
Q4 24
$194.5M
$593.7M
Q3 24
$288.0M
$506.2M
Q2 24
$254.8M
$1.0B
Total Debt
CLOV
CLOV
ST
ST
Q1 26
Q4 25
$2.8B
Q3 25
Q2 25
Q1 25
Q4 24
$3.2B
Q3 24
Q2 24
Stockholders' Equity
CLOV
CLOV
ST
ST
Q1 26
$2.9B
Q4 25
$308.7M
$2.8B
Q3 25
$340.9M
$2.7B
Q2 25
$344.2M
$2.9B
Q1 25
$336.1M
$2.8B
Q4 24
$341.1M
$2.9B
Q3 24
$342.2M
$3.0B
Q2 24
$324.9M
$3.0B
Total Assets
CLOV
CLOV
ST
ST
Q1 26
$6.8B
Q4 25
$541.0M
$6.8B
Q3 25
$559.7M
$7.1B
Q2 25
$575.0M
$7.3B
Q1 25
$583.7M
$7.2B
Q4 24
$580.7M
$7.1B
Q3 24
$653.0M
$7.3B
Q2 24
$674.2M
$8.2B
Debt / Equity
CLOV
CLOV
ST
ST
Q1 26
Q4 25
1.02×
Q3 25
Q2 25
Q1 25
Q4 24
1.11×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
ST
ST
Operating Cash FlowLast quarter
$-66.9M
$122.5M
Free Cash FlowOCF − Capex
$-69.0M
$104.6M
FCF MarginFCF / Revenue
-14.1%
11.2%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
1.41×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$508.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
ST
ST
Q1 26
$122.5M
Q4 25
$-66.9M
$201.5M
Q3 25
$12.1M
$159.9M
Q2 25
$5.4M
$140.9M
Q1 25
$-16.3M
$119.2M
Q4 24
$34.8M
$170.7M
Q3 24
$50.0M
$130.9M
Q2 24
$44.8M
$143.5M
Free Cash Flow
CLOV
CLOV
ST
ST
Q1 26
$104.6M
Q4 25
$-69.0M
$151.9M
Q3 25
$11.4M
$136.2M
Q2 25
$4.8M
$115.5M
Q1 25
$-16.5M
$86.6M
Q4 24
$33.3M
$138.9M
Q3 24
$49.6M
$91.3M
Q2 24
$44.4M
$98.4M
FCF Margin
CLOV
CLOV
ST
ST
Q1 26
11.2%
Q4 25
-14.1%
16.6%
Q3 25
2.3%
14.6%
Q2 25
1.0%
12.2%
Q1 25
-3.6%
9.5%
Q4 24
9.9%
15.3%
Q3 24
15.0%
9.3%
Q2 24
12.5%
9.5%
Capex Intensity
CLOV
CLOV
ST
ST
Q1 26
Q4 25
0.4%
5.4%
Q3 25
0.1%
2.5%
Q2 25
0.1%
2.7%
Q1 25
0.0%
3.6%
Q4 24
0.5%
3.5%
Q3 24
0.1%
4.0%
Q2 24
0.1%
4.4%
Cash Conversion
CLOV
CLOV
ST
ST
Q1 26
1.41×
Q4 25
3.19×
Q3 25
Q2 25
2.32×
Q1 25
1.70×
Q4 24
29.50×
Q3 24
Q2 24
6.04×
2.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons